GeneDx Faces Securities Lawsuit After Fabric Genomics Impairment

The litigation targets a class period spanning April 16, 2025, to May 4, 2026. According to the complaint, GeneDx touted the Fabric Genomics acquisition as a pillar of future efficiency, yet the unit failed to meet revenue targets by $2.5 million. This failure contributed to a massive surge in net losses, forcing the company to write off roughly 94% of the cash spent on the acquisition just one year prior.

Beyond the impairment, the company revealed a shift in product mix toward lower-revenue genome offerings and slashed its 2026 growth outlook by 12%. Reed Kathrein, the partner leading the investigation at Hagens Berman, stated that the firm is scrutinizing whether leadership knowingly presented a disconnect between public projections and internal financial reality. Amid this volatility, GeneDx appointed Mark Gardner as its new president. Investors who incurred significant losses have until August 3, 2026, to file as lead plaintiffs.